HIV Drugs, Abacavir and Didanosine Can Increased Risk of Heart Attack
European researchers Dr. Jens D. Lundgren, from the University of Copenhagen identified that HIV drugs, abacavir and didanosine can increase the risk of heart attacks.
“After collected data on 33,347 HIV patients who participated in the Data Collection on Adverse Events of Anti-HIV Drugs study (D:A:D)a number of drugs used to treat HIV patients We have identified Abacavir and Didanosine were indeed associated with an increased risk of a heart attack.” Dr. Jens D. Lundgren said. “However, if you have a very small underlying risk of heart attack, the risk will only be slightly increased,” Lundgren added.
For commonly used drugs called nucleoside reverse transcriptase inhibitors such as zidovudine, stavudine or lamivudine, the researchers found no association with an increased risk for heart attack.
However, the nucleoside reverse transcriptase inhibitors abacavir and didanosine were associated with an increased rate of heart attack, the researchers found. For patients taking abacavir, there was a twofold increased risk for heart attack. For those taking didanosine, the increased risk was about 50 percent.
“For those patients who have an increased underlying cardiovascular risk, then our suggestion is that these patients should consider whether there are other safer alternatives to these drugs,” Lundgren said. “If there are safer alternatives, then patients should consider switching to those.”
Abacavir (ABC) is a nucleoside analog reverse transcriptase inhibitor (NRTI) used to treat HIV and AIDS. It is available under the trade name Ziagen™ (GlaxoSmithKline} and in the combination formulations Trizivir™(abacavir, zidovudine and lamivudine) and Kivexa®/Epzicom™(abacavir and lamivudine) . It has been well tolerated: the main side effect is hypersensitivity, which can be severe and, rarely, fatal.
Didanosine (2′,3′-dideoxyinosine, ddI) is sold under the trade names Videx® and Videx EC®. It is a reverse transcriptase inhibitor, effective against HIV and used in combination with other antiretroviral drug therapy as part of highly active antiretroviral therapy (HAART).

